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Abstract
Background: COVID-19 has superseded all medical scientific challenges in 2020. It
presented with a range of respiratory involvement from the mild upper respiratory tract
to severe pneumonia with ARDS. A percentage of these patients manifested variable
neurological presentations expanding the challenges of patients’ assessment, care,
and management.
Objective: To discuss the neurological manifestations and the possible immunopathol-
ogy of COVID-19.
Methods: A literature search was performed in the PubMed database for the relevant
articles published in English language between April 9th , 2020 and June 1, 2020.
Few papers were extracted from Google Scholar and pre-print material as well. The
keywords used to perform search included “COVID-19,” “SARS Cov2,” “neurological
manifestations,” and “immunology and pathology of COVID-19”. However, animal
studies were excluded in the neurological manifestations, and the final number of
literature search outcome was 27 articles.
Results: The immunopathology involves angiotensin-converting enzyme (ACE)
receptor 2 and spike protein S1. COVID-19 has a tremendous affinity to the ACE2
receptor. The status of secondary hemophagocytic lymphohistiocytosis (sHLH) and
the cytokine storm lead to different organ damage and the corresponding clinical
manifestations. The documented neurological manifestations mainly include acute
ischemic stroke, hemorrhagic stroke, temporal lobe, thalamic encephalitis, and one
case of Guillain-Barre Syndrome, in addition to agitation, headache, and seizures.
Conclusion: Although the intimate relationship between the neurons and the immune
activation is the basic concept of COVID-19 immunopathology, the definite routes of
entry to the neuronal cells are yet to be disclosed. Acute stroke, myositis, headache,
and meningoencephalitis are the most common types of complications of COVID-19
so far.
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1. Introduction
COVID-19, which caused a global lockdown in 2020, exerts amajor health and economic
challenge. Starting at the molecular level, the genome of Corona Virus Disease 2019
(COVID-19) hasmany similarities with the severe acute respiratory syndrome coronavirus
(SARS-CoV) that caused the epidemic of 2003. Hence, the WHO initially named it
as SARS-CoV-2, which was later changed to COVID-19. Both viruses share the same
receptors to enter the cells that are the angiotensin-converting enzyme 2 receptor [1].
The major organs affected by COVID-19 are the lungs with rapidly fatal pneumonia,
occasionally requiring ventilatory support. The brain expresses a metallopeptidase,
ACE2 receptors in the glial cells and neurons. This can make the neurons a possible
goal for COVID-19 virus [2, 3]. The objective of this reviewwas to discuss the neurological
manifestations and the possible related immunopathology of COVID-19.
2. Methodology
For this narrative review, articles published in English language between April 9th , 2020
and June 1, 2020 were searched in PubMed database. A review of the bibliographies
from Google Scholar was performed to identify the supplementary papers that were
not originally found in the initial search. The terms “COVID-19” and “SARS Cov2” were
used and searched for the last five years. Only human studies for all ages and countries
were included in this study. Next, a search for immunology and pathology of COVID-
19 was done using the same inclusion criteria. Further, a cross-search using the term
“COVID-19” and “neurological manifestations” revealed some retrospective descriptive
studies from Wuhan, China and a few case reports. Two review articles were included,
in addition to few pre-print articles that met our search criteria. Moreover, the literature
with negative serology of COVID-19 and literature in other languages were excluded.
Animal studies were also excluded in the neurological manifestations. The final number
of literature search outcome was 27 articles.
3. Results
3.1. Immunopathology
The process involves activation of both innate and adaptive immunity. The ACE2
receptor affinity for SARS-Cov2 is mediated by the spike protein S1 which facilitates
the virus attachment to the cell wall. This receptor is expressed in the human airway
epithelia, lung parenchyma, vascular endothelial cells, kidneys, cardiac, testicular, and
small intestine. Another coronavirus, the Middle East respiratory syndrome (MERS-CoV)
enters human cells through Di-peptidyl peptidase 4 (DPP4) in the lower respiratory tract
and other tissues. COVID-19 has an average of 15-fold higher affinity for the spike protein
S1 than in SARS-Cov [1]. Hence, COVID-19 virus makes use of the ACE 2 receptors to
facilitate its cell entry to various target organs. The aforementioned proteins are not
the only mechanisms of virus cellular entry as some tissues failed to demonstrate the
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presence of ACE2 receptors but still got the virus documented such as some endothelial
and intestinal cells [2].
The immune system response in infectious conditions may differ from one human
to another depending on various genetic, racial, or environmental factors. However,
some will develop a secondary hemophagocytic lymphohistiocytosis (sHLH). During this
hyperinflammatory immune syndrome, there is a fatal and fulminant hypercytokinemia.
This is usually triggered by viruses in adults [4] and complicates around 4% of sepsis
cases [5]. Moreover, major cytokines may be involved in this process like IL-6, IL-1beta,
IL-2, IL-8, IL-17, G-CSF, GM/CSF, IP-10, MCP1, MIP1 alpha (CCL3), and TNF [6].
The mode of entry of the virus to the central nervous system (CNS) harbors many
theories such as the direct invasion, hematogenous/lymphatic spread, peripheral nerve
invasion, and trans-synaptic transmission [2]. Moreover, the ARDS patients are critically
ill patients and during their illness, they were noticed to have confounding metabolic
and toxic factors adding or creating an encephalopathic state. Other coronaviruses
may cause generalized motor seizures or subclinical epileptic activity in a less common
fashion [7, 8]. The inflammatory process may induce a thrombotic cascade leading to
a stroke. This is mediated by multiple factors which may include increased D-Dimers,
accelerated atherosclerosis, and dehydration [9]. The elevated D-Dimers are recognized
as a characteristic laboratory finding in COVID-19 infection. The C-reactive protein is also
elevated. Around 5% of COVID-19 patients develop ARDS, septic shock, and/or multiple
organ failure [6, 10]. They show a status of exhausted lymphocytes and lymphopenia
with a reduced number of CD4 T cells, CD8 T cells, B cells, and natural killer (NK)
cells. Also, the number of basophils, eosinophils, and monocytes are reduced [11]. Both
innate and adaptive immunities are activated with uncontrolled responses contributing
to tissue damage [12]. The condition exerts an increased IgG response and higher titers
of all antibodies; this status of antibody immune incontinence is associated with the
worst outcome [13]. Hence, this suggests an antibody-dependent enhancement (ADE)
of COVID-19 infection.
Besides, trans-nasal inoculation of SARS-Cov or MERS-Cov caused brain involvement
in transgenic mice mainly in the thalamus and brainstem. This caused high mortality in
infected mice without demonstration of lung involvement. In contrast to avian influenza
virus inoculation intranasally, SARS-Cov2 caused both brainstem and pneumonia.
The affected nuclei included the nucleus ambiguous and nucleus of the solitary
tract. The human body breathing reflex includes the action of the mechanoreceptors
and chemoreceptors in the lungs which sends their afferent impulses to the solitary
tract nucleus. The efferent fibers emerge from the solitary tract nucleus and nucleus
ambiguous to the airway smooth muscles, glands, and vascular bed [2]. This reflex is
interrupted during the viral infection by coronaviruses due to nuclei infection which
echoes the neuroinvasive tendency of the coronaviruses.
While in mice, the SARS-CoV managed to cause neuron death in the brain cells
through entry by the nose, cribriform plate, and olfactory bulb, in humans, the exact
route of entry to the neural cells by the SARS-Cov and MERS-Cov is not yet confirmed. It
is unlikely that it is through hematogenous or lymphatics because no virus was detected
in the non-neuronal tissues. However, there is some evidence that coronaviruses may
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enter through the peripheral nerves and travel to the CNS through synapses. Due to
similarities in the genomic structure, receptor vulnerability, respiratory involvement, the
SARS-Cov model can be used to suggest possible routes of entry to the neuronal cells
in COVID-19.
3.2. Neurological manifestations
The neurological manifestations in the brain for COVID-19 patients are still emerging as
the case fatality rises in Europe and USA. Coronaviruses can cause multiple systematic
involvements in various animals including humans. Along with the multiple factors which
add to the CNS involvement stand the elevated D-Dimers. The risk of a cerebrovascular
event is high during these changes, especially in the microcirculation which will be liable
to thrombosis or bleeding. The poor outcome in COVID-19 infection may be related to
age < 40 or > 60 years, high pyrexia, CRP, neutrophil counts, elevated liver enzymes,
high serum creatinine, and low platelets [14].
A pioneer pre-print work inWuhan gave an overall view of neurology and COVID-19 as
it described the neurological involvement in 214 COVID-19 patients through a review of
the electronic medical records. These were categorized into CNS, peripheral nervous
system (PNS), and muscle involvement [15]. The most common symptoms included
dizziness (16.8%) and headache (13.1%). The diagnoses of CNS involvement depend
on the CT findings, while muscle injury was determined by myalgia and Creatinine
Kinase CK level > 200 U/L. The latter may be attributed to the skeletal muscles
vasculitic process in COVID-19 as in SARS [16]. While the PNS involvement included
the symptomatology of hypogeusia (poor/loss of taste) without congestion and early
hyposmia (reduced sense of smell) [17, 18], in the same retrospective study, 24.8% had
CNS involvement, 8.9% had PNS, and 10.7% had skeletal muscle involvement [15].
Of all the patients, neurological manifestations were reported in 36.4% and were
more common in patients with severe infection, multiple co-morbidities (47%), mainly
hypertension (HT) and atypical symptoms (P-value < 0.05). Almost 45% of the patients
with severe infections developed neurological symptoms.
Specific disorders in these patients with severe infection included acute cerebrovas-
cular disease in 5.7% (80% of whom had an ischemic stroke), impaired consciousness in
14.8%, and muscle injury in 19.3%. All had significant P-values [15]. It is worth noticing that
the ischemic brain injury seems to follow the usual expected vascular pathology in stroke
patients being more ischemic than hemorrhagic. We expect this retrospective study to
be the cornerstone in the clinical context of COVID-19 neurology. This is because it
occurred in the early days of the virulent virus and when potential drugs were unknown
compared to a few months later. Therefore, immune system of those patients’ was left
to defend the virus only with the supportive measures.
The initial stroke percentage reported from Wuhan was 5.7% in which the majority
was ischemic in nature in severe cases. One percent of non-severe COVID-19 patients
developed a stroke. Older people with co-morbidities were more prone to develop
a cerebrovascular event than younger patients with COVID-19 infection [9]. One case
report of a middle-aged female presenting with the classical symptoms and positive
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COVID-19 serology had associated confusion. The CT Brain showed bilateral hypo-
attenuation signals on the thalami. The MRI showed “evidence of hemorrhagic rim
enhancing lesions within the bilateral thalami, medial temporal lobes, and sub insular
regions” [19].
The ALBACOVID registry which was recently published included a larger group of
patients (841) in Spain and stroke occurred in 1.7% of patients. These were severe cases
[20].
In one report of large vessel acute stroke in five young (below 50 years of age) COVID-
19 patients, the National Institute of Health and Stroke Scale (NIHSS) mean score was
17, indicating severe disability. Four patients had reduced consciousness level and one
had hemiplegia. Only one patient was discharged home and the others were in ICU
or rehabilitation units [21]. Hence, both large and small vessels are liable to vascular
insults (vasculitis) reflecting their tendency to be caught in the severe inflammatory storm
caused by COVID-19 infection. The radiological changes have proved involvement of
different anatomical/vascular brain structures. This may suggest direct virus invasion of
brain tissues as reported in MERS-Cov/ SARS-Cov.
As the COVID-19 puzzle is unfolding slowly, emerging neurological recommendations
are coming through on the same speed. In the acute ischemic stroke setting, after the
activation of the stroke code in case of the available stroke team, or if not, one doctor
or resident with full PPE (personal protective equipment) should be exposed to the
suspected case till the patient returns from radiology. This will reduce the risk during
donning and doffing of PPE. If thrombolysis was indicated, the same doctor will remain
inside the room while the patient is in radiology and during the first hour of Tissue
Plasminogen Activator (TPA) infusion. Monitoring the patient requires filling of the q15
minute neuro-check; this can be performed by the doctor/resident/nurse inside the
room. The clinical (including NIHSS) and imaging results should be discussed over
the phone with the neurologist. In high-risk patients presenting with impaired GCS
or large hemispheric infarctions, remote clinical assessment through video techniques
(iPAD/Phone) should be performed. However, in high- or low-risk groups, concerns of
bedside assessment can be revealed by the bedside neurologist assessment with PPE
[22]. It is important to add here that there are no concerns about the inter-rater reliability
in NIHSS assessment between different persons as it was appraised previously [23].
In the post-thrombectomy patients via catheter intervention, remote checks of the
groin complications may be performed according to the recommendations and to avoid
the risk of COVID-19 infection [24]. Imaging repetition is not generally recommended
[22].
The other workup package includes all other relevant tests like Trans Esophageal
Echo (TEE), Carotid Doppler, and Brain MRI should be delayed unless there is an
endocarditis. It is also worth knowing that in general for acute stroke patients, the MRI
is unlikely to exert major management changes [25]. A recent French study reported a
bilateral frontotemporal hypoperfusion in 18%, asymptomatic lacunar strokes in 3%, and
an established stroke in 1.7% of COVID-19 patients [26].
In cases of intracranial hemorrhage, the same initial steps apply here. The follow-up
CT, in general, may be done 3–6 hr later as up to 40% of stroke patients may develop
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a clinically significant expansion of hematoma [27]. The prognosis will be worsened in
case of COVID-19 positive patients due to the involvement of other organs.
Severe neurological involvement in the brain has been documented before in MERS
CoV [28]. Hence, in our expectations, few COVID-19 cases may develop subarachnoid
hemorrhage (SAH) due to accelerated atherosclerosis and the effect of the inflammation
on the stability of intracranial aneurysms [29]. The management of these patients should
consider, in addition to the aforementioned points, the maintenance of euvolemia to
prevent overload in ARDS, early intubation for large SAH, shorten ICU stay/early external
ventricular drainage (EVD) clamp (avoid vasospasm), and the use of prophylaxis against
DVT as COVID-19 patients have higher coagulability state [22].
The conclusion for acute stroke patients in the setting of COVID-19 infection is that
it is more encountered in severe COVID-19 infection and they are mainly ischemic in
nature with high disability. Specific management largely depends on the consultation
of the stroke team. Then, the benefit–risk ratio should be assessed in the scope of
infection control. The protocol recommends using teleneurology to minimize exposure,
decide on the frequency of assessments, and relevant radiology for stroke in these
highly infectious patients [22].
The severe inflammatory response causes ARDS in half of the patients. Hence, it can
result in hemorrhagic encephalitis affecting various areas in the brain [30]. In a newer
study observing neurological manifestations of SARS2 in an ICU in Strasbourg France,
agitation was reported in 69% of patients enrolled. Before the ICU admission, 14%
had neurological manifestations, while 67% were observed to have it after cessation of
neuromuscular block and sedation. This is not easy to be solely due to the virus effect on
the brain as many metabolic, pharmacological, and inflammatory factors are involved. A
high percentage (67%) developed diffuse pyramidal signs with hyperreflexia and clonus.
At the time of discharge, 34% had executive disturbances, inattention, disorientation,
and disorganized movements. The encephalopathic features necessitated MRI imaging
which showed leptomeningeal enhancement in 13%. The leptomeningeal signs and the
frontotemporal signs may support the neuroinvasive character of the virus. However,
the final PCR results did not support this. The Electroencephalogram (EEG) showed non-
specific changes in 14%. Cerebrospinal fluid (CSF) was acellular in 12%, while matched
oligoclonal bands (OCB) were reported in 3.4%. Only one patient had high protein and
IgG levels in the CSF. In 12% of the patients, the CSF PCR tested negative for COVID-
19 [26]. It seems that the variation of CSF immune and cytology findings reflects the
variable immune mechanisms by which the virus may affect the neural tissues.
The first case to be reported as associated with encephalitis was described in a
24-year old man. His symptoms started with headache, fever, and malaise. On the
second day, the patient was reviewed and treated as influenza by Laninamivir plus
antipyretics. However, on day five, the patient deteriorated with a sore throat and
worsening headache. The blood tests and CXR were reassuring. On the ninth day,
he was found collapsed with surrounding vomitus. In the ER he presented with low
GCS and developed a generalized motor seizure which recurred later multiple times.
The patient had neck stiffness indicating meningio-encephalitis. There was evidence
of neutrophil leukocytosis with leukopenia and high CRP. His nasopharyngeal swab
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for COVID-19 was negative but the CT chest was suggestive. Lumber puncture (LP)
showed a clear CSF with high opening pressure > 320 mmH2O, with cells of 12/µL (10
mononuclear and 2 polymorphonuclear). No antibodies against Herpes were detected,
however, the RNA of COVID-19 was detected in the CSF. On day one, the brain MRI
diffusion-weighted images showed hyperintensities along with the inferior horn of the
lateral ventricle on the right side. The Fluid Attenuation Inversion Recovery (FLAIR),
on the other hand, showed hyperintense signals on the medial temporal lobe and
hippocampus with slight hippocampal atrophy. This also documents the meningeal
component besides the encephalitis process. This represents the first documented
case of COVID-19 encephalitis with negative nasopharyngeal swab testing by PCR [31].
It seems that there is a predilection for the temporal lobes as herpes simplex virus but
this is too early to be generalized. A single case of encephalitis was also reported in
the ALBACOVID registry.
Currently, there are no clear guidelines for the treatment of the encephalopathic
state in COVID-19 patients. The general measures apply and further steps depend on
the outcome of relevant neuro-medical tests and the decision of the neurologist.
The pioneering study of 214 patients in Wuhan reported headache to be a symptom in
13.1%. This is quite similar to 14.1% of the ALBACOVID registry. On the other hand, a study
enrolled 62 patients and although headache as a symptom was higher (34%), the later
study targeted patients with human-to-human transmission only [32]. In a retrospective
study in Wuhan which enrolled 41 positive patients for COVID-19, 8% had a headache
[6]. However, in the largest study with 262 patients, headache was reported in 6.2%,
and it was the lowest among all studies [33]. In a smaller group of 30 medical workers,
headache was reported in 53.3% [34]. The headache symptom was also reported in
the first case of encephalitis with COVID-19. The variation reported in headache reflects
that headache is a common presenting symptom of COVID-19 infection and the average
percentage may be around 25%. The management of chronic headache types with
acute exacerbation in this setting is by using a combination of IV paracetamol, triptans,
and different antiemetics. The use of opioids should be avoided so as not to degrade
the respiratory effort. The symptomatic treatment by NSAIDs is not carrying a sufficient
risk to worsen the infection depending on the available literature evidence [35]. Further
evaluation of headache is needed if there are changes in the neurological examination
or GCS or if it is a thunderclap headache. In these situations, the Boston Medical Center
recommends proceeding for brain CT and LP if SAH is suspected. We think that the
primary cause of headache in COVID-19 infection is not easy to separate as being a
manifestation of the systemic immune changes or the direct involvement of the brain
as proved in few cases either by imaging or CSF analysis. The accumulation of more
headache-related literature in the setting of COVID-19 patients may reveal the final
result.
Muscles constitute a large bulk of human body and are expected to be involved in
the severe inflammatory process of COVID-19. While most of the literature has reported
myalgia as a common feature of the infection that may occur in many viruses, where
in one study, it was found in 44% of the patients [6], a lower percentage of 17.2% was
reported from the ALBACOVID registry [20]. Another case report on an elderly female
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with multiple co-morbidities reported myalgia starting early in her deadly COVID-19
infection. Myalgia was also reported in middle-aged female air workers as a common
symptom. In most of them, the Creatinine Kinase (CK) levels were > 200 IU plus high
inflammatory markers. This suggests a degree of muscle damage (myositis). It may not
be severe enough to cause primary muscle weakness but the common occurrence and
the persistence and associated elevation of muscle enzymemakes it a genuine immune
characteristic of the virus and extends its target cells from neurons to muscle fibers.
The real epidemiological statistics of seizures in COVID-19 are still to be determined.
However, in other coronaviruses’ infections, seizures were estimated to range between
6% and 50% [7]. The recent report which reviewed 841 patients in Spain reported rarity of
seizures in COVID positive patients as the percentage was only 0.7% [20]. It is expected
that some will manifest clinical motor or other subclinical seizures. The underlying
pathophysiology will range between the direct invasion in areas like temporal lobes,
the disturbed hemostasis, and metabolic state. The former structure is well-known for
its association with focal to bilateral sensory-motor seizures, and the stressful immune
activation associated with COVID-19 may easily affect the electrical stabilization of this
area. Moreover, the relevant imaging showed involvement of temporal lobes in some
cases either on one or both sides. The Boston Medical Center recommendations in the
management of the acute motor seizures in COVID- 19 follows the standard protocol
with caution in cases with liver or kidney injuries. In liver disturbances, Brivaracetam,
lacosamide, levetiracetam, or zonisamide may be preferred. The EEG recording should
be discussed with the technician and the neurologist first to meet the fundamental
goal of risk reduction. Patients with impaired consciousness may need continuous EEG
monitoring to detect subclinical seizures, and this needs to be tailored according to the
risk–benefit ratio [22].
The loss of taste and smell proved common neurological presentation in even mild
disease. The ALBACOVID reported anosmia in 4.9% and dysgeusia in 6.2% [20].
For patients with suspected Guillain-Barre Syndrome (GBS) with COVID-19 infection,
the initial assessment follows the standard neurological assessment with special focus
on the signs of respiratory failure and pulmonary function testing. The point of care
is preferred to be the ICU especially if we considered the risk of dysautonomia. The
relevant investigations like Nerve Conduction Studies (NCS) and LP may be delayed if
the clinical diagnosis is obvious as these tests are equivocal in up to 50% of cases in the
first week. Moreover, the high risk in contracting the infection from these patients may
have affected the detailed electrophysiological classification of myoneuropathy in them
[36]. The standard GBS therapeutic measures apply in COVID-19 situation [22]. The
options include the intravenous immune globulins infusions or the plasma exchange.
Till April 12, 2020, only one case assumed to have an acute GBS associated with
COVID-19 infection was reported. The case scenario mentioned that four days after
returning from the index city of Wuhan, a 61-year-old lady developed remarkable fatigue
and acute lower limbs weakness. This was not accompanied by the cardinal symptoms
of COVID-19 infection or respiratory failure. Her signs included power 4/5 muscle
weakness, absent reflexes, and abnormal light touch and pin prick sensations. The
NCS confirmed a form of demyelinating neuropathy while the blood counts showed
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lymphopenia and thrombocytopenia. After receiving the intravenous immune-globulins
(IVIG), on day 8 she started to develop fever, dry cough, typical radiological features
on CT scan as ground-glass appearance, and tested positive for COVID-19. In the
third week, her blood counts normalized, and by the fourth week, she recovered
completely including the tendon reflexes in the four limbs. The authors discussed the
casual association in this case between GBS and COVID-19 in detail as the para-
infectious rather than post-infectious neuropathy in this setting. However, they did
not explain the sensory signs which are recognized in a small percentage of GBS
subtype and the NCS which is expected to be normal in the first week in a significant
percentage of patients. Hence, we believe that this may represent other para-infectious
sensory-motor neuropathy which seems to be mild with good recovery. Since GBS
is an autoimmune disease and molecular mimicry is the main immunopathological
mechanism in its etiology, we find it difficult to confirm this case given the lack of CSF and
autoantibodies result. The recruitment of other similar cases may reveal the ambiguity
of the association [37]. However, in June, one case of GBS was described in the
ALBACOVID registry [20]. The same study reportedmyopathy in 3.1% and dysautonomia
in 2.5%. In conclusion to GBS and Covid-19 the association seems to be a rare one.
Despite that the preventionmay lay out of the scope of this narrative review, COVID-19
exerted strict health and economical preventionmethods. Neurology is not an exception
in this worldwide trend.
The prevention protocol is essential for patients with known PNS disorders as they
can contract the infection from the community or their caregivers. The adherence to the
international/national guidelines of movement restriction, use of PPE, and restriction
of hospital follow-up are of paramount importance. In the case of seropositive test,
any pre-existing neurological disease will exert its negative effect on the outcome
and the intensive care measures. This can be hypothetically generalized for other
similar conditions especially hereditary and congenital muscle diseases. A target group
here may include patients with Myasthenia Gravis, motor neuron disease, neurologic
respiratory involvement, and kyphoscoliosis, all of which tend to have a poor respiratory
reserve escalating morbidity and mortality profile. Patients with < 60% predicted FVC
(forced vital capacity) are unlikely to wean from ventilation and patients with < 40%
FVC are likely to be on NIPPV (noninvasive positive-pressure ventilation) already [38].
The septic status and prolonged stay in the ICU will increase the likelihood of critical
illness neuromyopathy which adds to the negative outcome and functional disabilities
[39]. Neurological complications may emerge due to non-virus causes like hypoxia,
secondary hypercoagulable state, disseminated intravascular coagulopathy, and drug
toxicities.
Another emerging puzzle is the use of immunosuppressive during COVID-19 infec-
tions in patients with multiple sclerosis (MS), autoimmune neuropathy, and autoimmune
encephalitis that are susceptible to immune-related complications. These diseases
represent the peak of neuronal immune activation withmany questions pending solution
and made worse by COVID mystery. Medications like high-dose steroids, Natalizumab
(Tysabri), other monoclonal antibodies are yet to be investigated for their role in adding
to the immune disturbance/mortality in concomitant COVID-19 infection. The association
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of British Neurologist released their recommendations about the safe use of Natal-
izumab, Dimethyl Fumarate (Tecfidera), Interferon beta 1a & 1b, Teriflunomide, and Glati-
ramer acetate. While the Fingolimod (Gilenya) carried a moderate risk, a significant risk
was suggested with the Alemtuzumab, Cladribine (Mavenclad), Ocrelizumab, Rituximab,
Siponimod, and Ofatumumab. This may not match the recommendations for individual
drugs in other publications [40]. A conservative recommendation indorses cautious use
of highly efficient medications. This may be paralleled by rebound activation of the
disease, making the balance difficult [41].
Many strategies were recommended to treat different categories of neurological
patients during the pandemic of COVID-19. This included the hereditary ataxia patients
especially during the prevention and control period of COVID-19 fatal pneumonia.
Elderly with late-stage dementia, and young syndromic patients are also at high risk
of complications. Other minor neurological symptoms encountered by the authors and
related to the COVID-19 situation rather than the virus itself included self-limiting sensory
ulnar neuropathy due to remote overworking from home, postauricular pain due to N95
straps, and mask-induced headaches.
All the navigated neurological manifestations during this infection may reflect the
diversity of the symptomatology or the complications of the pre-existing diseases in
such group of patients which constitutes a high risk for COVID-19.
4. Conclusion
The extreme immunological storm caused by the virus results in a secondary
hemophagocytic lymphohistiocytosis (sHLH) ending with serious pathological damage
to the lungs, brain, muscles, and kidneys. The virus has a huge affinity to the ACE
2 receptor placing the brain as a target organ. Headache is a common symptom of
COVID-19 infections and affects around one-quarter of cases while myalgia affects
almost half of them. Stroke in the setting of COVID-19 infection can affect both large
vessels in < 50 years and small vessels in older patients with severe infection. Intra-
cerebral hemorrhage is less common. The primary pathology for stroke seems to be
vasculitic as well as for the muscles. The encephalopathic features may be multifactorial
but at least in part are strongly related to the neuroinvasion by the virus as previously
documented in MERS-CoV and SARS-CoV. This is supported by abnormal CSF findings
in some of these patients and positive PCR for COVID-19. Seizures may be caused by
affection of the temporal lobes as shown in some cases. PNS involvement is uncommon
in COVID-19 infection, while the loss of smell and taste are common symptoms even in
patients with mild infection. The later symptoms may support the route of entry of the
virus being near to the cranial neural structures. The final epidemiological pattern for
the neurological manifestations of COVID-19 is yet to be revealed after the pandemic
fades away.
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Disclaimer
The views mentioned in the conclusion represent the professional authors’ opinions
and not their corresponding institutions.
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